AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Nimble Therapeutics for $200 million in cash, with additional potential milestone-based payments. The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease (IBD), along with other novel oral peptide candidates for autoimmune diseases.
The deal also encompasses Nimble's proprietary peptide synthesis, screening, and optimization platform, which accelerates the discovery and optimization of peptide candidates. The IL23R inhibitor targets a clinically validated therapeutic pathway in autoimmune diseases, particularly affecting psoriasis and IBD pathogenesis through increased inflammation and amplified immune responses.
AbbVie (NYSE: ABBV) ha annunciato un accordo definitivo per acquisire Nimble Therapeutics per 200 milioni di dollari in contanti, con ulteriori potenziali pagamenti legati a obiettivi specifici. L'acquisizione include l'asset principale di Nimble, un inibitore orale del peptide IL23R in fase di sviluppo preclinico per la psoriasi e la malattia infiammatoria intestinale (IBD), insieme ad altri candidati a peptide orale innovativi per malattie autoimmuni.
L'accordo comprende anche la piattaforma proprietaria di sintesi, screening e ottimizzazione dei peptidi di Nimble, che accelera la scoperta e l'ottimizzazione dei candidati peptidici. L'inibitore dell'IL23R mira a un percorso terapeutico clinicamente convalidato nelle malattie autoimmuni, influenzando in particolare la patogenesi della psoriasi e della IBD attraverso l'aumento dell'infiammazione e la amplificazione delle risposte immunitarie.
AbbVie (NYSE: ABBV) ha anunciado un acuerdo definitivo para adquirir Nimble Therapeutics por 200 millones de dólares en efectivo, con pagos adicionales potenciales basados en hitos. La adquisición incluye el activo principal de Nimble, un inhibidor de péptido oral IL23R en desarrollo preclínico para la psoriasis y la enfermedad inflamatoria intestinal (EII), junto con otros candidatos a péptidos orales novedosos para enfermedades autoinmunes.
El acuerdo también abarca la plataforma propietaria de síntesis, detección y optimización de péptidos de Nimble, que acelera el descubrimiento y la optimización de candidatos a péptidos. El inhibidor de IL23R se dirige a una vía terapéutica clínicamente validada en enfermedades autoinmunes, afectando particularmente la patogénesis de la psoriasis y la EII a través del aumento de la inflamación y la amplificación de las respuestas inmunitarias.
AbbVie (NYSE: ABBV)는 Nimble Therapeutics를 2억 달러에 현금으로 인수하기 위한 확정 계약을 발표했으며, 추가적인 이정표 기반의 지불이 있을 수 있습니다. 이 인수에는 Nimble의 주요 자산인 임상 전 개발 중인 경구용 펩타이드 IL23R 억제제가 포함되어 있으며, 이는 건선 및 염증성 장 질환(IBD) 치료를 위한 것입니다. 또한 자가면역 질환을 위한 기타 혁신적인 경구용 펩타이드 후보들도 포함됩니다.
이번 거래는 Nimble의 독점 펩타이드 합성, 스크리닝 및 최적화 플랫폼도 포함되며, 이는 펩타이드 후보의 발견 및 최적화를 가속화합니다. IL23R 억제제는 자가면역 질환에서 임상적으로 검증된 치료 경로를 목표로 하며, 특히 건선 및 IBD 병인론에 대한 염증 증가와 면역 반응의 증폭을 통해 영향을 미칩니다.
AbbVie (NYSE: ABBV) a annoncé un accord définitif pour acquérir Nimble Therapeutics pour 200 millions de dollars en espèces, avec des paiements supplémentaires potentiels basés sur des étapes. L'acquisition comprend l'actif principal de Nimble, un inhibiteur de peptide oral IL23R en développement préclinique pour le psoriasis et la maladie inflammatoire de l'intestin (MII), ainsi que d'autres candidats en peptides oraux novateurs pour les maladies auto-immunes.
L'accord comprend également la plateforme propriétaire de synthèse, de criblage et d'optimisation des peptides de Nimble, qui accélère la découverte et l'optimisation des candidats à peptides. L'inhibiteur IL23R cible une voie thérapeutique cliniquement validée dans les maladies auto-immunes, affectant particulièrement la pathogénèse du psoriasis et de la MII par l'augmentation de l'inflammation et l'amplification des réponses immunitaires.
AbbVie (NYSE: ABBV) hat eine endgültige Vereinbarung zum Erwerb von Nimble Therapeutics für 200 Millionen US-Dollar in bar angekündigt, einschließlich zusätzlicher möglicher milestonesbasierter Zahlungen. Die Akquisition umfasst Nimble's Hauptvermögen, einen experimentellen oralen Peptid-IL23R-Inhibitor in der präklinischen Entwicklung zur Behandlung von Psoriasis und entzündlicher Darmerkrankung (IBD) sowie andere neuartige orale Peptidkandidaten für Autoimmunerkrankungen.
Der Deal umfasst auch Nimble's proprietäre Peptidsynthese-, Screening- und Optimierungsplattform, die die Entdeckung und Optimierung von Peptidkandidaten beschleunigt. Der IL23R-Inhibitor zielt auf einen klinisch validierten therapeutischen Ansatz in Autoimmunerkrankungen ab und beeinflusst insbesondere die Pathogenese von Psoriasis und IBD durch erhöhte Entzündungen und verstärkte Immunantworten.
- Acquisition price of $200 million is structured with upfront cash payment
- Adds preclinical-stage oral peptide IL23R inhibitor for psoriasis and IBD treatment
- Gains proprietary peptide synthesis and optimization platform technology
- Expands pipeline in autoimmune diseases with multiple novel oral peptide candidates
- Lead asset still in preclinical stage, indicating long development timeline before potential commercialization
- Additional milestone payments could increase total acquisition cost
- Transaction subject to regulatory approval and waiting period
Insights
- Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain
- Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics
"The addition of Nimble's pipeline to AbbVie's existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases."
"Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases," said Jigar Patel, Ph.D., founder and chief executive officer, Nimble Therapeutics. "The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline."
Nimble's preclinical-stage IL23R inhibitor is an investigational oral therapy for the treatment of psoriasis and inflammatory bowel disease (IBD). IL23R is a clinically validated therapeutic target in certain autoimmune diseases and a major contributing factor to psoriasis and IBD pathogenesis and progression through increased inflammation and amplified immune responses.
Under the terms of the agreement, AbbVie will make a cash payment of
Nimble is backed by founding investors Telegraph Hill Partners and Roche Ventures.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Nimble Therapeutics
Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods. Nimble is located in
No Offer or Solicitation
This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. Forward looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward looking statements, and AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-acquire-nimble-therapeutics-further-strengthening-immunology-pipeline-302331351.html
SOURCE AbbVie
FAQ
What is the acquisition price AbbVie (ABBV) is paying for Nimble Therapeutics?
What is the main asset AbbVie (ABBV) is acquiring from Nimble Therapeutics?
What technology platform is AbbVie (ABBV) gaining through the Nimble acquisition?
What therapeutic areas will the ABBV-Nimble acquisition target?
When is the ABBV-Nimble acquisition expected to close?
